Human retinal pigment epithelial cell therapy

Drug Profile

Human retinal pigment epithelial cell therapy

Alternative Names: ACT hESC-RPE; hESC-derived RPE; hRPE cell therapy; Human embryonic stem cell (hESC)-derived retinal pigment epithelium (RPE) cells - Astellas; MA09-hRPE; RPE cell therapy - Astellas

Latest Information Update: 04 May 2017

Price : $50

At a glance

  • Originator Advanced Cell Technology
  • Developer Astellas Pharma; CHA Bio & Diostech
  • Class Eye disorder therapies; Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Stargardt disease
  • New Molecular Entity No

Highest Development Phases

  • Phase II Age-related macular degeneration; Stargardt disease
  • Preclinical Degenerative myopia

Most Recent Events

  • 30 Jan 2017 Phase-II clinical trials in Stargardt disease 1 in USA (Intraocular) (Astellas Pharma pipeline, January 2017)
  • 14 Jul 2016 University of California, Los Angeles and Ocata Therapeutics withdraws a phase I/II trial prior to enrolment in Degenerative myopia in USA (NCT02122159)
  • 03 Jun 2016 Astellas Pharma suspends enrolment in a phase-II clinical trials for Age-related macular degeneration in USA (Intraocular) (NCT02563782)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top